SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2011 / Cilt: 59 - Sayı: 1

Effects of inhaled corticosteroids/long-acting beta-2 agonist fix combinations in COPD

KOAH’da inhaler kortikosteroid/uzun etkili beta-2 agonist fiks kombinasyonunun etkileri

Mehmet POLATLI
Nurhayat YILDIRIM
TUNÇALP DEMİR
Hakan GÜNEN
Pages
89–100
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The clinical trials in the last 10 years revealed that fix combinations (inhaled corticosteroids/long-acting beta-2 agonist; ICS/LABA) improve lung functions and quality of life, and reduced symptoms and exacerbation rates in patients with severe and very severe COPD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized with progressive air flow limitation, and is expected to be the third leading cause of death until 2030 worldwide.
📊
Key Findings & Data:Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized with progressive air flow limitation, and is expected to be the third leading cause of death until 2030 worldwide.
💡
Conclusion & Impact:The clinical trials in the last 10 years revealed that fix combinations (inhaled corticosteroids/long-acting beta-2 agonist; ICS/LABA) improve lung functions and quality of life, and reduced symptoms and exacerbation rates in patients with severe and very severe COPD.
🔬Design:Research Article
📍Scope:2030 Verileri
⚙️Variables:Domain Parameters

Abstract

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized with progressive air flow limitation, and is expected to be the third leading cause of death until 2030 worldwide. The clinical trials in the last 10 years revealed that fix combinations (inhaled corticosteroids/long-acting beta-2 agonist; ICS/LABA) improve lung functions and quality of life, and reduced symptoms and exacerbation rates in patients with severe and very severe COPD.

Özet

Kronik obstrüktif akciğer hastalığı (KOAH) progresif hava akımı kısıtlanması ile karakterize ve 2030 yıllarında dünyada üçüncü ölüm nedeni olacağı tahmin edilen inflamatuvar bir hastalıktır. Son 10 yılda yapılan çalışmalar fiks kombinasyonun (inhaler kortikosteroid/uzun etkili beta-2 agonist; İKS/LABA) ağır ve çok ağır KOAH olgularında akciğer fonksiyonlarını ve yaşam kalitesini iyileştirdiğini, semptomları ve atak sıklığını azalttığını göstermiştir.

🔖

Cite This Article

POLATLI, M., YILDIRIM, N., DEMİR, T., GÜNEN, H. (2022). Effects of inhaled corticosteroids/long-acting beta-2 agonist fix combinations in COPD. Tüberküloz ve Toraks, Cilt: 59 - Sayı: 1, 89–100. https://ajindex.com/articles/619058

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rennard SI, Barnes PJ. Pathogenesis of COPD. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC (eds). Asthma and COPD. London: Academic Press, 2002: 361-79
  2. Chung KF. Cytokines in COPD. Eur Respir J 2001; 34 (Suppl): 50-9
  3. Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 2003; 22: 94-9
  4. Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable COPD: relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999; 160: 1486-92
  5. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-72
  6. Hall IP. β-2 adrenoceptor agonists. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC (eds). Asthma and COPD. London: Academic Press, 2002: 521-6
  7. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90
  8. Hui KP, Ventresca P, Brown AC, et al. Modulation of neurally mediated airway microvascular leak in guinea pig airways by beta-2 adrenoceptor agonists. Agents Actions 1992; 32: 29-33
  9. Hansel TT, Barnes PJ. Drug therapy for stable COPD. In: Hansel TT, Barnes PJ (eds). An Atlas of COPD. London: The Parthenon Publishing Group, 2004: 135-200
  10. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704-12
  11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org Updated 2009. 12. www.nice.org.uk/CG101 13. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J 2003; 21: 74-81
  12. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in COPD. Eur Respir J 2003; 22: 912-9
  13. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate/salmeterol combination delivered via the discus device in the treatment of COPD. Am J Respir Crit Care Med 2002; 166: 1084-91
  14. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of COPD. A randomized controlled trial. Lancet 2003; 361: 449-56
  15. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and